Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's Lymphoma
Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
MOR208, a monoclonal antibody directed against the antigen CD19, was given to patients for at least 3 months. In the DLBCL subgroup a 30% objective response rate was achieved, with most responses being durable and some continuing beyond 2-years. MOR208 is a relatively non-toxic treatment and a potential target for future combinations regimens, said Jurczak. The 30% response rate was more than expected, he says.
In the indolent lymphoma cohort, the protocol was poorly designed, says Jurczak. Most of the patients responded, however nearly half had stable disease and as such therapy was not continued after the first cycle. Those who responded did have a prolonged progression-free-survival, he says.
<<<
